Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases

Journal of Clinical Investigation

Volumn 100, Issue 1, 1997, Pages 149-157

  Santra, Manoranjan ^a   Mann, David M ^b,c   Mercer, Edward W ^d   Skorski, Thomas ^d   Calabretta, Bruno ^d   Iozzo, Renato V ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b HOLLAND LABORATORY   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cell division; Proliferation; Proteoglycans; Stable transfection

Indexed keywords

CYCLIN DEPENDENT KINASE; DECORIN; PROTEIN P21;

ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL PROLIFERATION; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; PROTEIN TRANSPORT;

EID: 0030798869     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119507     Document Type: Article

References (42)

1. Iozzo, R.V. 1997. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 32:141-174.
2. Iozzo, R.V., and A.D. Murdoch. 1996. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB (Fed. Am. Soc. Exp. Biol.) J. 10:598-614.
3. Danielson, K.G., H. Baribault, D.F. Holmes, H. Graham, K.E. Kadler, and R.V. Iozzo. 1997. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 136:729-743.
4. Border, W.A., N.A. Noble, T. Yamamoto, J.R. Harper, Y. Yamaguchi, M.D. Pierschbacher, and E. Ruoslahti. 1992. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (Lond.). 360:361-364.
5. Isaka, Y., D.K. Brees, K. Ikegaya, Y. Kaneda, E. Imai, N.A. Noble, and W.A. Border. 1996. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. 2:418-423.
6. Yamaguchi, Y., and E. Ruoslahti. 1988. Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature (Lond.). 336:244-246.
7. Yamaguchi, Y., D.M. Mann, and E. Ruoslahti. 1990. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature (Lond.). 346:281-284.
8. Coppock, D.L., C. Kopman, S. Scandalis, and S. Gilleran. 1993. Preferential gene expression in quiescent human lung fibroblasts. Cell Growth Differ. 4: 483-493.
9. Mauviel, A., M. Santra, Y.Q. Chen, J. Uitto, and R.V. Iozzo. 1995. Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-α. J. Biol. Chem. 270:11692-11700.
10. Iozzo, R.V., and I. Cohen. 1993. Altered proteoglycan gene expression and the tumor stroma. Experientia (Basel). 49:447-455.
11. Adany, R., R. Heimer, B. Caterson, J.M. Sorrell, and R.V. Iozzo. 1990. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J. Biol. Chem. 265:11389-11396.
12. Iozzo, R.V. 1985. Neoplastic modulation of extracellular matrix. Colon carcinoma cells release polypeptides that alter proteoglycan metabolism in colon fibroblasts. J. Biol. Chem. 260:7464-7473.
13. Santra, M., T. Skorski, B. Calabretta, E.C. Lattime, and R.V. Iozzo. 1995. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. USA. 92:7016-7020.
14. De Luca, A., M. Santra, A. Baldi, A. Giordano, and R.V. Iozzo. 1996. Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 271:18961-18965.
15. 1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
16. Mann, D.M., Y. Yamaguchi, M.A. Bourdon, and E. Ruoslahti. 1990. Analysis of glycosaminoglycan substitution in decorin by site-directed mutagenesis. J. Biol. Chem. 265:5317-5323.
17. Krusius, T., and E. Ruoslahti. 1986. Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc. Natl. Acad. Sci. USA. 83:7683-7687.
18. 1 arrest and apoptosis. Cancer Res. 54:1169-1174.
19. Scholzen, T., M. Solursh, S. Suzuki, R. Reiter, J.L. Morgan, A.M. Buchberg, L.D. Siracusa, and R.V. Iozzo. 1994. The murine decorin. Complete cDNA cloning, genomic organization, chromosomal assignment and expression during organogenesis and tissue differentiation. J. Biol. Chem. 269:28270-28281.
20. Danova, M., M. Giordano, G. Mazzini, and A. Riccardi. 1990. Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leuk. Res. 14:417-422.
21. RB) in osteosarcomas and synovial sarcomas. Oncogene Res. 4:205-214.
22. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805-816.
23. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
24. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:59-66.
25. Waldman, T., C. Lengauer, K.W. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond.). 381:713-716.
26. Polyak, K., T. Waldman, T.-C. He, K.W. Kinzler, and B. Vogelstein. 1996. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1945-1952.
27. Iozzo, R.V. 1995. Tumor stroma as a regulator of neoplastic behavior. Lab. Invest. 73:157-160.
28. Ruoslahti, E., and Y. Yamaguchi. 1991. Proteoglycans as modulators of growth factor activities. Cell. 64:867-869.
29. Waga, S., G.J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.). 369:574-578.
30. Vogel, K.G., and J.A. Trotter. 1987. The effects of proteoglycans on the morphology of collagen fibrils formed in vitro. Collagen Relat. Res. 7:105-114.
31. Koyama, H., E.W. Raines, K.E. Bornfeldt, J.M. Roberts, and R. Ross. 1996. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1069-1078.
32. Travers, H., N.S. French, and J.D. Norton. 1996. Suppression of tumorigenicity in Ras-transformed fibroblasts by α2(I) collagen. Cell Growth Differ. 7: 1353-1360.
33. Morgan, D.D. 1995. Principles of CDK regulation. Nature (Lond.). 374: 131-134.
34. Pines, J. 1995. Cyclins, CDKs and cancer. Semin. Cancer Biol. 6:63-72.
35. Harper. J.W., S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Tsai, P. Zhang. S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, et al. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell. 6:387-400.
36. Weber, I.T., R.W. Harrison, and R.V. Iozzo. 1996. Model structure of decorin and implications for collagen fibrillogenesis. J. Biol. Chem. 271:31767-31770.
37. Steinman, R.A., B. Hoffman, A. Iro, C. Guillouf, D.A. Libermann, and M.E. El-Houseini. 1994. Introduction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 9:3389-3396.
38. Michieli, P., M. Chedid, D. Lin, J.H. Pierce, W.E. Mercer, and D. Givol. 1994. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54: 3391-3395.
39. WAF1/CIP1/SDI1 in differentiating human leukemic cells. J. Clin. Invest. 95:973-979.
40. ras in inhibition/regulation of platelet-derived growth factor (PDGF) type-β receptor activation. Oncogene. 12:1213-1222.
41. WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ. 7:893-901.
42. Buttke, T.M., J.A. McCubrey, and T.C. Owen. 1993. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods. 157:233-240.